Here are six notes:
1. The increasing demand for new neurostimulation techniques will drive market growth.
2. The rise in cerebral stroke, Alzheimer’s disease, epilepsy and Parkinson’s disease cases will also spur market growth.
3. Neurostimulation devices accounted for more than 50 percent of market revenue in 2014.
4. In 2014, North America dominated the market because of advanced healthcare infrastructure, favorable government initiatives and neurological research and development investment.
5. Asia-Pacific will see a compound annual growth rate of more than 8 percent to 2022, due to unmet medical needs and increased healthcare research and development investment.
6. Key market players include Johnson & Johnson, B. Braun Melsungen, Boston Scientific, St. Jude Medical, Medtronic, Magstim, W.L. Gore & Associates, Integra Life Sciences Holdings and Stryker.
More articles on devices:
PODs under attack again: 5 key notes from the Senate Finance Committee’s report
DJO Global reports Q1 12.7% net sales growth, $38.3M net loss: 7 key notes
Camber Spine Technologies launches two new products
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
